Allergan gets a lift from assessment that threat to Botox is overblown

29th November 2017 Uncategorised 0

Allergan has been facing a lot of criticism of late, what with a sagging share price, pressure for a breakup and blowback on a maneuver to protect eye drug Restasis from generics. But it has gotten a little love from analysts at Morgan Stanley which raised their outlook for the drugmaker.

More: Allergan gets a lift from assessment that threat to Botox is overblown
Source: fierce